LEP and Hepatic steatosis: In this study, loganin treatment inhibited HFD- and OVX-induced weight gain and fat deposition reduced metabolic abnormalities, such as hepatic steatosis and adipocyte expansion, and increased the plasma levels of insulin and leptin.